Rosiglitazone maleate ( DrugBank: Rosiglitazone )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2
75	クッシング病	1
265	脂肪萎縮症	1

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-000482-35-LT (EUCTR)	08/11/2005	26/09/2005	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis. - HM2004/00255/03	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis. - HM2004/00255/03	Rheumatoid Arthritis	Product Name: Rosiglitazone Extended Release Tablets Product Code: BRL-049653 INN or Proposed INN: Rosiglitazone Other descriptive name: Rosiglitazone maleate	GlaxoSmithKline Research & Development Ltd.	NULL	Not Recruiting			Female: yes Male: yes	96		United Kingdom;Lithuania
2	EUCTR2004-000482-35-GB (EUCTR)	11/10/2004	08/02/2005	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis. - HM2004/00255/00	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis. - HM2004/00255/00	Rheumatoid Arthritis	Product Name: Rosiglitazone Extended Release Tablets Product Code: BRL-049653 INN or Proposed INN: Rosiglitazone Other descriptive name: Rosiglitazone maleate	GlaxoSmithKline Research & Development Ltd.	NULL	Not Recruiting			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Lithuania;United Kingdom

75. クッシング病

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00612066 (ClinicalTrials.gov)	April 2007	8/2/2008	Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)	An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease	Cushing's Disease	Drug: rosiglitazone maleate	Jonsson Comprehensive Cancer Center	National Institutes of Health (NIH)	Terminated	18 Years	65 Years	All	2	Phase 2	United States

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00015691 (ClinicalTrials.gov)	April 2001	1/5/2001	Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities	A Randomized, Double-Blind, Placebo-Controlled Study of Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Subjects With Hyperinsulinemia and Elevated Waist/Hip Ratio	HIV Infections;Lipodystrophy;Hyperinsulinemia	Drug: Metformin hydrochloride;Drug: Rosiglitazone maleate	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	65 Years	Both	105	N/A	United States